| Jennifer Ferguson, CCC-SLP | |
|
18280 Sterling Hwy, (online Services Only), Cooper Landing, AK 99572 | |
| (251) 554-2516 | |
| Not Available |
| Full Name | Jennifer Ferguson |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 18280 Sterling Hwy, Cooper Landing, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205556503 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 118306 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Ferguson, CCC-SLP Po Box 609, Cooper Landing, AK 99572-0609 Ph: () - | Jennifer Ferguson, CCC-SLP 18280 Sterling Hwy, (online Services Only), Cooper Landing, AK 99572 Ph: (251) 554-2516 |
News Archive
The healthy heart movement in recent years has focused largely on heart disease as the No. 1 killer of women. But the same statistic is true for men, and the reality is grim: The first sign that a man has coronary heart disease could be death, says one University of Alabama at Birmingham expert.
An enzyme known for its role in heart disease may well be a promising target to treat asthma. Researchers from the University of Iowa have found that the enzyme, called CaMKII, is linked to the harmful effects of oxidation in the respiratory tract, triggering asthmatic symptoms.
A federal push for more transparency in how states run their Medicaid programs is pitting patient advocates and medical providers against state officials who fear being hamstrung. The transparency effort comes as states seek ever greater flexibility in how they manage their Medicaid programs to cope with historic budget woes.
New research from the Canadian Longitudinal Study on Aging shows that adults who have low fruit and vegetable intakes have a higher likelihood of being diagnosed with an anxiety disorder.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.
› Verified 3 days ago